Neurology dep., Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Neurology dep., Faculty of Medicine, Ain Shams University, Cairo, Egypt.
J Stroke Cerebrovasc Dis. 2021 Sep;30(9):105956. doi: 10.1016/j.jstrokecerebrovasdis.2021.105956. Epub 2021 Jun 30.
Leukoaraiosis (LA) is a finding in the elderly, that might be asymptomatic or can impact their motor and cognitive functions. We studied the presence of LA in the MRI of patients with AIS and its impact on functional outcome at 3 months.
500 consecutive patients diagnosed as AIS were enrolled. Medical history included pre-medication by antiplatelets or statins, and vascular risk factors were reported by history and laboratory investigations. Severity of stroke was assessed by NIHSS and stroke outcome was evaluated on discharge and at 3 months by modified Rankin scale (mRS). LA was diagnosed by MRI-FLAIR sequence and delineated from acute infarction by diffusion-weighted image. And accordingly, patients were divided into group A (absent LA) and group B (present LA).
460 patients completed the study, with 53% of patients on antiplatelet therapy and 11.7% on statins prior to stroke. The percentage of patients with LA was significantly more than those without LA. Patients with LA showed a significantly higher age, more frequent and longer duration of diabetes and hypertension, ischemic heart disease, previous stroke/TIA and antiplatelet intake. Microbleeds were more and mRS was worse in LA group.
The presence of LA in the background MRI of AIS patients is accompanied by the presence of more risk factors, and unfavorable outcome. Pre-medication with antiplatelets did not prevent the incidence of a new stroke especially in LA group. This might necessitate the identification of some medication for secondary prevention in patients with small vessel disease.
脑白质疏松症(LA)在老年人中较为常见,可无症状,也可影响其运动和认知功能。我们研究了急性缺血性脑卒中(AIS)患者 MRI 中 LA 的存在情况及其对 3 个月时功能结局的影响。
连续纳入 500 例诊断为 AIS 的患者。病史包括抗血小板或他汀类药物的预处理,血管危险因素通过病史和实验室检查报告。通过 NIHSS 评估卒中严重程度,通过改良 Rankin 量表(mRS)在出院时和 3 个月时评估卒中结局。通过 MRI-FLAIR 序列诊断 LA,并通过弥散加权图像将其与急性梗死区分开。相应地,患者分为 A 组(无 LA)和 B 组(有 LA)。
460 例患者完成了研究,抗血小板治疗的患者占 53%,卒中前他汀类药物治疗的患者占 11.7%。有 LA 的患者比例明显高于无 LA 的患者。有 LA 的患者年龄较大,糖尿病和高血压、缺血性心脏病、既往卒中和 TIA 以及抗血小板治疗的发生率和持续时间更高。LA 组的微出血更多,mRS 更差。
AIS 患者背景 MRI 中存在 LA 伴有更多的危险因素和不良结局。抗血小板预处理并不能预防新卒中的发生,特别是在 LA 组。这可能需要确定一些针对小血管疾病患者的二级预防药物。